

Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies

Elena Olmastroni¹, Giulia Molari², Noemi De Beni¹, Ornella Colpani¹,
Federica Galimberti^{1,2}, Marta Gazzotti¹, Alberto Zambon^{2,3},
Alberico L. Catapano^{1,2}, and Manuela Casula ^{1,2*}

¹Department of Pharmacological and Biomolecular Sciences, Epidemiology and Preventive Pharmacology Service (SEFAP), University of Milan, Via Balzaretti 9, 20133 Milan, Italy; ²IRCCS MultiMedica, Via Milanese 300, 20099 Sesto S. Giovanni (MI), Italy; and ³Department of Medicine—DIMED, University of Padua, Via Giustiniani 2, 35128 Padua, Italy

Received 2 September 2021; revised 10 November 2021; editorial decision 20 November 2021; accepted 24 November 2021

Aims

As the potential impact of statins on cognitive decline and dementia is still debated, we conducted a meta-analysis of observational studies to examine the effect of statin use on the risk of Alzheimer's disease (AD) and dementia.

Methods and results

PubMed, Cochrane, and EMBASE were searched since inception to January 2021. Inclusion criteria were: (i) cohort or case–control studies; (ii) statin users compared to non-users; and (iii) AD and/or dementia risk as outcome. Estimates from original studies were pooled using restricted maximum-likelihood random-effect model. Measure of effects were reported as odds ratio (OR) and 95% confidence intervals (CIs). In the pooled analyses, statins were associated with a decreased risk of dementia [36 studies, OR 0.80 (CI 0.75–0.86)] and of AD [21 studies, OR 0.68 (CI 0.56–0.81)]. In the stratified analysis by sex, no difference was observed in the risk reduction of dementia between men [OR 0.86 (CI 0.81–0.92)] and women [OR 0.86 (CI 0.81–0.92)]. Similar risks were observed for lipophilic and hydrophilic statins for both dementia and AD, while high-potency statins showed a 20% reduction of dementia risk compared with a 16% risk reduction associated with low-potency statins, suggesting a greater efficacy of the former, although a borderline statistical significance ($P=0.05$) for the heterogeneity between estimates.

Conclusion


These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. Randomized clinical trials with an *ad hoc* design are needed to explore this potential neuroprotective effect.

* Corresponding author. Tel: +39 02 5031 8428, Email: manuela.casula@unimi.it

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Graphical Abstract



Keywords

Statins • Alzheimer's disease • Dementia • Meta-analysis • Observational studies

Introduction

Statins are a class of cholesterol-lowering drugs with proven cardiovascular benefits, validated in different groups of patients.¹ Statins are the cornerstone of pharmacotherapy for atherosclerotic cardiovascular disease, and with the increasing epidemiological burden of hypercholesterolaemia^{2,3} and as newer more stringent lipid goals recommended by latest guidelines,^{1,4} their use is increasingly growing, making statins one of the most commonly prescribed medications worldwide. The role of statins in primary and secondary prevention of cardiovascular disease has been highlighted by the efficacy and safety results reported in a large number of randomized controlled trials and meta-analyses investigating the effects of statins in primary and secondary prevention populations and in subgroups.^{5,6} For each 1 mmol/L reduction in LDL cholesterol, statin reduced the relative risk of major cardiovascular events by 22%, major coronary events by 23%, and coronary artery disease death by 20%. Although cholesterol

reduction is the major effect of statins, a number of other, potentially important, effects have been suggested (pleiotropic effects). Among such effects that may be potentially relevant for the onset and clinical progression of dementia and cognitive decline are the anti-inflammatory and antioxidant effects of statins as well as the effect on blood flow and suppression of reactive oxygen species.⁷ Statins are generally well-tolerated and have an excellent safety profile but, as with all drugs, adverse reactions may occur in some patients.^{8,9}

Case reports have brought to the attention the reported adverse effect of statin use on cognition,^{10–12} including memory loss, which led in 2012 the US Food and Drug Administration to issue a black box warning for possible adverse effects of statins on cognitive performance. Consumer concerns regarding potential adverse effects of statins are prevalent, so that memory and/or cognitive changes are the second most frequently reported adverse effect during statin therapy.¹³ These concerns can compromise acceptance or adherence to statin medications essential to reduce atherosclerotic

cardiovascular risk. With increasing body of evidence, short-term data suggest a lack of adverse effect of statins on cognition, while long-term data seem to support a beneficial role for statins in the prevention of dementia.^{14,15} Large-scale trials did not find that statin treatment was associated with dementia or cognitive test scores,^{16,17} while in small-scale trials the results have been mixed.^{18–20} Also, evidence from observational studies have provided inconsistent results so far,^{21–23} with meta-analyses showing variable effects, depending on type of included studies, type of outcome, and characteristics of statins.^{22,24,25}

Considering this background, the aim of this study is to provide an updated systematic review and meta-analysis of all observational studies reporting data on the risk of Alzheimer's disease (AD) and/or dementia, in individuals treated with statins compared with subjects not receiving a lipid-lowering therapy.

Methods

This systematic review and meta-analysis has been performed and reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses Of Observational Studies in Epidemiology) guidelines and recommendations.^{26,27} Because all the analyses were performed on the basis of previous published studies, no ethical approval or informed consent was required.

Search strategy

A systematic and comprehensive literature search was performed on Pubmed, EMBASE databases, and Cochrane Library to retrieve eligible articles from inception to January 2021. Search strategy comprised a combination of terms relevant to the research question, including 'dementia', 'Alzheimer', and 'statin' with Boolean operators as appropriate (see [Supplementary material online](#)). The search was restricted to English language and articles available as full text (studies published as abstract were excluded, as well as letters, comments, editorials, case reports).

Studies selection

According to PRISMA guidelines, all records retrieved from the search were systematically and sequentially screened, according to titles and abstracts. Each article included after the abstracts screening phase was independently evaluated for full-text eligibility. Any disagreement during each phase was resolved by discussion with a third author.

We included studies which met the following criteria: (i) observational studies (cohort or case–control studies); (ii) adult subjects; (iii) statin users compared to non-users; and (iv) reporting an adjusted estimate [such as odds ratio (OR)/risk ratio (RR)/hazard ratio] and 95% confidence intervals (CIs) for AD and/or dementia risk as outcome. References of included studies were additionally reviewed for other relevant articles, which were not retrieved from the literature search. In case of two or more studies based on the same cohort of subjects and exploring the same outcome(s), only the most recently published was selected and included in the meta-analysis.

Outcomes definition

Primary outcomes were AD and dementia defined according to clinical criteria, as the United States National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA),²⁸ the International Classification of Diseases-10/9th edition (ICD-9-CM/ICD-10),²⁹ the

American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders-IV-TR (DSM),³⁰ or the mini-mental state examination (MMSE) or its modified version (3MSE).³¹

Data extraction and quality assessment

Data from the included studies were extracted independently by two authors. Data on sample size, method used for the outcomes definition, estimates of the association of interest, were extracted using a standardized electronic form. Additionally, we collected data about study design and cohort baseline characteristics (i.e. age and sex).

All included studies were also independently evaluated by two co-authors to assess the risk of several bias. Screening was performed for five main bias categories (selection bias, performance bias, attrition bias, detection bias, and reporting bias). An overall, synthetic grade was produced for each study. The methodological quality of the included studies was evaluated based on the items of modified Newcastle-Ottawa Scale, comprising patient selection, study group comparability and outcome assessment.³² The observational studies scored 0 to 9. Divergent opinions were discussed among authors and a consensus was reached.

Statistical analysis

Outcomes from original studies were pooled and compared using DerSimonian–Laird random-effects method. Measure of effects were reported as OR and 95% CIs. The *I*-square (*I*²) test was adopted to evaluate the influence of heterogeneity on the output of the meta-analysis. *I*² values of 0%, 25%, 50%, and 75% represented no, low, medium, and high heterogeneity, respectively. Heterogeneity was tested using Cochran Q statistic and the *I*² metric.³³ A *P*-value of <0.05 was accepted as statistically significant. Publication bias was evaluated visually by examining the funnel plot measuring the standard error as a function of effect size, as well as statistically by using the Egger test.³⁴ We then performed a subanalysis based on patients aged ≥75 years, as well as several stratified analyses according to study design (cohort or case–control studies), sex (men or women), type of statin [predominantly 'hydrophilic' statins (rosuvastatin and pravastatin) or predominantly 'lipophilic' statins (atorvastatin, simvastatin, lovastatin, and fluvastatin)],³⁵ and statin potency ['high potency' statins (atorvastatin, rosuvastatin, and simvastatin) or 'low potency' statins (any other statins)] as defined by included studies. A test of between-group differences based on the *Q*_b statistic is also reported. This test investigates the difference between the group-specific overall effect sizes.


The analyses and the corresponding graphical visualization of forest and funnel plots were conducted using both STATA Version 16 and R Software Program Version 4.0.2.

The data underlying this article are available in the article and in its online supplementary material.

Results

Descriptive study characteristics

The flow diagram of the literature searches and study selection is shown in [Figure 1](#). Finally, 46 observational studies (38 cohort studies and 8 case–control studies) were included in the meta-analysis. The main characteristics of the studies are summarized in [Table 1](#). All these studies were published between 2000 and January 2021. Samples sizes ranged from 123 to 2 004 692 patients, and 14 out of 46 studies reported a mean participant age ≥75 years old. All studies were of high methodological quality, with only one study reporting a Newcastle-Ottawa scale score of 5 points ([Supplementary material](#)



online, Figure S1). In total, 25 studies reporting adjusted estimates only for dementia risk, 10 only for AD risk, and 11 studies reporting estimates for both the outcomes.

Meta-analyses results

Overall, 36 observational studies (N 5 738 737) were included in the analysis of dementia risk (Figure 2). We found that statin use was associated with a decreased risk of dementia [OR 0.80 (CI 0.75–0.86)]. Similarly, the analysis of 21 studies (N 1 188 377) showed a significant 32% reduction in the risk of AD among statin users [OR 0.68 (CI 0.56–0.81)] (Figure 3). Visual examination of funnel plots and

statistical testing of data from the observational studies for each outcome revealed an apparent publication bias only for dementia risk (Supplementary material online, Figure S2A and B).

The subgroup analysis of patients aged ≥ 75 years confirmed a statin-associated risk reduction, yielding a 18% reduction in the risk of dementia [OR 0.82 (CI 0.72–0.93)] and 27% reduction in the risk of AD [OR 0.73 (CI 0.54–0.98)] (Supplementary material online, Figure S3A and B).

In subgroup analyses by type of study design (cohort or case–control), no apparent effect modification was found for both the outcomes. Pooled estimates confirmed the risk reduction for dementia, both in cohort studies and in case–control studies [OR 0.81 (CI

Table 1 Characteristics of observational studies included

Study	Design	N° total	Age (minimum as for inclusion criteria; mean)	Sex (% M)	Outcomes	Diagnostic test	Newcastle-Ottawa scale score
Jick <i>et al.</i> 2000 ³⁶	CC	1364	≥50; NA	39.5	D	NINCDS-ADRDA	7
Rockwood <i>et al.</i> 2002 ³⁷	CC	1315	≥65; 78.05	38.0	D, AD	3MSE	8
Yaffe <i>et al.</i> 2002 ³⁸	Co	1037	None; 71.1	0.0	D	3MSE	6
Zamrini <i>et al.</i> 2004 ³⁹	CC	3397	None; 73	100.0	AD	ICD-9-CM	7
Li <i>et al.</i> 2004 ⁴⁰	Co	2356	≥65; 75.1	40.2	D	DSM-IV, NINCDS-ADRDA	8
Reitz <i>et al.</i> 2004 ⁴¹	Co	1168	≥65; 78.4	33.3	AD	NINCDS-ADRDA	7
Rea <i>et al.</i> 2005 ⁴²	Co	2798	≥65; 75.0	40.1	D, AD	NINCDS-ADRDA	6
Zandi <i>et al.</i> 2005 ⁴³	Co	5092	≥65; 74.4	45.0	D, AD	DSM-III-R, NINCDS-ADRDA, 3MSE	8
Green <i>et al.</i> 2006 ⁴⁴	CC	2378	None; 67.0	38.6	AD	NINCDS-ADRDA	7
Szwast <i>et al.</i> 2007 ⁴⁵	Co	1146	≥70; 77.3	30.7	D	DSM-III-R, ICD-10	8
Wolozin <i>et al.</i> 2007 ⁴⁶	Co	1 290 071	≥65; 74.6	94.4	D	ICD-9	6
Zigman <i>et al.</i> 2007 ⁴⁷	Co	123	None; 51.2	22.8	AD	consensus conference (clinical agreement)	5
Sparks <i>et al.</i> 2008 ⁴⁸	Co	2068	≥70; 74.7	45.7	AD	DSM-IV, NINCDS/ADRDA	7
Arvanitakis <i>et al.</i> 2008 ⁴⁹	Co	929	>40; 74.9	31.3	AD	MMSE	8
Cramer <i>et al.</i> 2008 ⁵⁰	Co	1674	≥60; 70.2	41.7	D	DSM-IV, NINCDS-ADRDA, 3MSE	7
Smeeth <i>et al.</i> 2009 ⁵¹	Co	729 529	None; NA	50.3	D, AD	clinical chart record	8
Haag <i>et al.</i> 2009 ⁵²	Co	6992	None; 69.4	40.0	AD	DSM-III-R, NINCDS-ADRDA	7
Hippisley-Cox <i>et al.</i> 2010 ⁵³	Co	2 004 692	≥30; 45.8	49.4	D	clinical chart record	6
Li <i>et al.</i> 2010 ⁵⁴	Co	3099	≥65; 75.4	40.5	AD	DSM-IV, NINCDS-ADRDA	7
Beydoun <i>et al.</i> 2011 ⁵⁵	Co	1604	≥50; 57.6	61.5	D	DSM-III-R, NINCDS-ADRDA	7
Parikh <i>et al.</i> 2011 ⁵⁶	Co	377 838	≥65; 75.5	97.9	D	ICD-9-CM	6
Bettermann <i>et al.</i> 2012 ⁵⁷	Co	3069	≥75; 78.6	53.8	D, AD	3MSE, ADAS-Cog	7
Ancelin <i>et al.</i> 2012 ⁵⁸	Co	6830	≥65; 73.7	39.7	D, AD	DSM-IV, NINCDS-ADRDA	8
Douiri <i>et al.</i> 2013 ⁵⁹	Co	1682	None; NA	53.9	D	MMSE, AMT	7
Chen <i>et al.</i> 2014 ⁶⁰	CC	27 716	≥50; 77.5	48.8	D	ICD-9-CM	7
Chen <i>et al.</i> 2014 ⁶¹	Co	18 170	≥50; 66.8	52.3	D, AD	ICD-9-CM	7
Chou <i>et al.</i> 2014 ⁶²	Co	103 637	≥60; NA	46.1	D, AD	ICD-9-CM	8
Ma <i>et al.</i> 2014 ⁶³	Co	634	≥65; 75.3	0.0	AD	NINCDS-ADRDA	8
Lin <i>et al.</i> 2015 ⁶⁴	Co	1438	≥50; NA	30.8	AD	ICD-9-CM	8
Chao <i>et al.</i> 2015 ⁶⁵	Co	256 265	≥60; 73.2	49.7	D	ICD-9-CM	8
Chuang <i>et al.</i> 2015 ⁶⁶	Co	123 300	≥20; 54.6	49.1	D	ICD-9-CM	8
Yang <i>et al.</i> 2015 ⁶⁷	Co	3688	≥65; NA	33.9	D	ICD-9-CM	8
Hendrie <i>et al.</i> 2015 ⁶⁸	Co	974	None; 76.6	30.3	D, AD	DSM-IV, ICD-10	6
Chitnis <i>et al.</i> 2015 ⁶⁹	Co	8062	None; 74.5	47.0	D	ICD-9-CM	8
Wu <i>et al.</i> 2015 ⁷⁰	CC	4006	≥65; 72.9	49.9	D	ICD-9-CM	8
Booker <i>et al.</i> 2016 ⁷¹	CC	23 912	≥70; 80.4	39.0	D	ICD-10	7
Pan <i>et al.</i> 2018 ⁷²	Co	9448	≥20; 62.5	55.0	D	ICD9-CM	8
Wändell <i>et al.</i> 2018 ⁷³	Co	12 096	≥45; 72.3	54.4	D	ICD-10	7
Liu <i>et al.</i> 2018 ⁷⁴	Co	2012	None; 74.3	NA	D	ICD-9-CM	8
Redelmeier <i>et al.</i> 2019 ⁷⁵	Co	28 815	≥65; 76	38.7	D	ICD-9-CM	8
Chang <i>et al.</i> 2019 ⁷⁶	Co	100 610	None; 71.7	46.0	D	ICD-9-CM	8
Kim <i>et al.</i> 2020 ⁷⁷	Co	143 174	≥65; 72.2	40.3	D	ICD-10	8
Lee <i>et al.</i> 2020 ⁷⁸	Co	112 036	≥50; NA	48.4	D	ICD-9-CM	7
Lee <i>et al.</i> 2020 ⁷⁹	Co	6182	≥40; 66.6	38.6	D, AD	ICD-10	7
Torrancell-Haro <i>et al.</i> 2020 ⁸⁰	Co	288 515	≥45; 66.6	45.1	D, AD	ICD-9-CM	9
Zingel <i>et al.</i> 2020 ⁸¹	CC	24 472	≥65; 80.2	42.3	D	ICD-10	8

3MSE, Modified Mini-Mental State Examination; AD, Alzheimer's disease; ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; CC, case-control study; Co, cohort study; D, dementia; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; M-ACE, The Mini-Addenbrooke's Cognitive Examination; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NA, not available; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.




Figure 2 Meta-analysis of statin use and dementia risk.

0.74–0.88) and OR 0.85 (CI 0.77–0.93), respectively, [Supplementary material online, Figure S4A](#)], and for AD [OR 0.70 (CI 0.58–0.84) and OR 0.56 (CI 0.41–0.78), respectively, [Supplementary material online, Figure S4B](#)]. The Q_b statistic suggested no differences between estimates for both dementia and AD risks ($P=0.43$ and $P=0.27$, respectively).

In the stratified analyses by sex, men and women showed the same reduction in the risk of dementia [both OR 0.86 (CI 0.81–0.92), [Supplementary material online, Figure S5A](#)]. We observed a non-significant reduction in the risk of AD both for men [OR 0.71 (CI 0.47–1.06)] and women [OR 0.85 (CI 0.48–1.49)], but this evaluation has been limited by the low number of studies reporting this information ([Supplementary material online, Figure S5B](#)).

Furthermore, lipophilic and hydrophilic statins induced similar reductions in the risk of dementia [OR 0.83 (CI 0.76–0.90) and OR 0.80 (CI 0.71–0.89), respectively, [Supplementary material online, Figure S6](#)] and AD [OR 0.61 (CI 0.46–0.81) and OR 0.59 (CI 0.43–

0.82), respectively, [Supplementary material online, Figure S6](#)]. Also in this case, the Q_b statistic suggested no differences between estimates for both dementia and AD risk ($P=0.61$ and $P=0.88$, respectively).

Finally, in the stratified analysis by statin potency, high-potency and low-potency statins showed a similar reduction in the risk of dementia [OR 0.80 (CI 0.72–0.88) and OR 0.84 (CI 0.79–0.90), respectively, [Supplementary material online, Figure S7](#)]. However, the Q_b statistic showed a borderline statistical significance ($P=0.05$), suggesting a possible heterogeneity between estimates and leaving open the possibility of a greater efficacy of high-potency statins in reducing the risk of developing dementia.

Discussion

Our up to date meta-analysis of 46 observational studies evaluating the association between statin therapy and the incidence of neurocognitive diseases showed that the use of statins not only did not increase the risk of neurocognitive disorders, but rather was associated with a significant risk reduction of 20% of dementia and 32% reduction of AD. This effect was confirmed in the analysis by study design, emphasizing the robustness of this evidence. The benefit was confirmed in both men and women, without any difference in the risk reduction of dementia (-24% in both groups) and with a non-significant risk reduction for AD, probably due to low number of studies reporting the stratified estimates and to heterogeneity among studies.

Our results are in line with a recent meta-analysis including only prospective studies in patients with mean age ≥ 60 years without cognitive impairment at baseline⁸² as well as other previous pooled evaluations with different sets of inclusion criteria.^{22,83,84}

The majority of the studies included middle-aged adults, a key age-range for an effective cardiovascular disease prevention strategy but also to highlight the potential modulation by statin treatment of cognitive function in the decades ahead. However, our stratified analysis suggests that the beneficial effect of statins is also present in subjects at higher risk of developing dementia due to older age. In the study by Chou et al.,⁶² the 20% risk reduction observed in the general population ≥ 60 years was shown to be similar in the subgroup analysis performed according to age (60–69, 70–79, and ≥ 80 years). Other studies provide evidence of the protective effects of statins also in subjects at higher risk of developing dementia due to predisposing conditions. Chen et al.⁶¹ analysed the incidence of AD among 28 321 patients diagnosed with type 2 diabetes and ≥ 50 years, showing that a regular statin use was associated with a 13% risk reduction. Zigman et al.⁴⁷ reported similar evidence in an analysis of patients with Down syndrome, a condition that increases dramatically the risk of dementia also at relatively younger ages. Moreover, an early statin use was significantly associated with risk reduction in studies evaluating the progression of dementia in subjects with mild cognitive impairment.^{57,64}

We also stratified our meta-analysis based on the type of statins: hydrophilic and lipophilic statins appear to produce similar and significant reductions in the risk of dementia and AD. This is in contrast with previous studies reporting a protective effect limited to lipophilic statins.⁸⁵ Interestingly, in the study by Wu et al.,⁷⁰ the analysis of the effect of different statins showed that higher doses of high-potency statins (atorvastatin and rosuvastatin) had the strongest




Figure 3 Meta-analysis of statin use and risk of Alzheimer’s disease.

protective effect, suggesting that the potency of statin, rather than drug lipophilicity, was the major factor in reducing dementia. This seems to be confirmed also in our stratified analysis by statin potency, where high-potency statin use was associated with a 20% risk reduction compared with a reduction of 16% of dementia associated with low-potency statins. Our updated meta-analysis included also recent studies, in which the use of rosuvastatin was superior than in the past. Assuming a greater effect for high-potency statins, we might expect the increased use of hydrophilic rosuvastatin in more recent studies to narrow the gap that was observed in previous studies between hydrophilic and lipophilic statins. Indeed, in the analysis by Redelmeier et al.,⁷⁵ the relative risk of dementia with rosuvastatin (accounting for 20% of total statin prescriptions and 70% of hydrophilic statin prescriptions) was 0.78 (95% CI 0.67–0.91), driving the

risk reduction with hydrophilic statins [RR 0.76 (95% CI 0.67–0.86), compared to 0.91 (95% CI 0.84–0.98) for lipophilic statins]. However, we have also to note that a potential confounding factor in these studies might be represented by the different baseline clinical phenotypes and cardiovascular risk of patients taking high-potency vs. low/medium-potency statins.⁸¹

There may be several mechanisms by which statins exert effects on cognition. It has been suggested that some statins may cross the blood–brain barrier and modulate brain cholesterol metabolism, directly altering neurotransmission and synaptic plasticity,⁸⁶ but this hypothesis is still debated. Statins have also been shown to reduce oxidative stress and inflammation, increase endothelial nitric oxide synthase, and improve endothelial function and blood flow.⁸⁷ Furthermore, the statin-mediated effect on cognition could be simply

related to their ability in reducing blood cholesterol. However, data from the Hebbinghaus study,⁸⁸ where a PCSK9 monoclonal antibody was used, and extremely low LDL cholesterol levels achieved, in the range of 0.8 mmol/L or less, showed no cognitive function deterioration and there were no associations between LDL cholesterol levels and cognitive changes. Further evaluations are needed to clarify this aspect.

A growing body of evidence suggests a close association between lipids and vascular changes in dementia. Hyperlipidaemia, particularly in mid-life, seems to be associated with an increased risk of dementia, potentially by promoting damage to the brain vasculature. Consequently, treating hyperlipidaemia would be expected to reduce the risk of dementia.²¹ The hypothesis that statins reduce the risk of dementia by reducing LDL cholesterol levels is supported by the results of studies in which statin use was unrelated to dementia risk for participants with desirable cholesterol levels, but it was associated with a reduced risk in participants with high-cholesterol levels.^{38,47} Moreover, this is in line with evidence from Mendelian randomization studies showing that low LDL-C levels due to 3-hydroxy-3-methylglutaryl-CoA reductase genetic variants did not appear to increase the risk of AD or dementia,^{89,90} as included subjects have lower cholesterol levels since birth, and supports the observation of a greater benefit with high-potency statins.⁷⁰ However, this hypothesis is reasonable for dementia with multifactorial aetiology and for AD with a relevant ischaemic component, whereas it may not be relevant in 'pure' AD forms linked to ApoE genotype and at early onset, which however are rare, particularly among participants in observational studies on statin use.

In the elderly cohort of the Cardiovascular Health Study, Bernick et al.⁹¹ showed that the use of statins was associated with a slight reduction in the rate of cognitive decline during a 7-year period, compared with individuals not taking statins, independently of baseline serum lipid levels. In a subset of participants who underwent two magnetic resonance imaging scans, no differences were observed in white matter or atrophy measures between statin-users and untreated subjects. However, untreated but drug-eligible patients had a greater accumulation of silent subcortically infarcts than the statin-treated group, suggesting the possibility that the accelerated cognitive decline in the statin eligible but untreated participants was due to subclinical vascular disease.

Discordant observations in AD patients might indeed be influenced by the variable degree of concurrent ischaemic cerebrovascular lesions, which may impact the effect of statins on the atherothrombotic contribution to the cognitive decline seen in AD patients. The relative abundance of ischaemic lesions and the predictable impact of aggressive LDL-C-lowering therapy vs. the potential direct effect of statins on amyloid- β or other pathophysiological mechanism(s) of AD might account for the observed different clinical outcomes associated to statin therapy.

The evidence of a neuroprotective effect of statins emerges from observational studies, but not clinical trials.⁹² The only long-term randomized trial in the elderly population is the PROSPER (Prospective Study of Pravastatin in Elderly at Risk), which reported comparable cognitive function declines in patients treated with pravastatin or placebo.^{17,93} The Simvastatin Heart Protection Study found no effect on cognitive impairment or dementia after 5 years of

follow-up, but the study did not control for dementia risk factors, and dementia ascertainment did not follow the rigorous standards required currently.¹⁶ Moreover, the relatively short follow-up time and a low incidence of dementia may limit drawing conclusions. In the recent Heart Outcomes Prevention Evaluation-3 (HOPE-3) study,⁹⁴ which evaluated whether cardiovascular medications can delay cognitive decline, participants were randomized to candesartan plus hydrochlorothiazide or placebo and to rosuvastatin (10 mg) or placebo, using a 2 × 2 factorial design. The primary cognitive outcome measure was change in DSST (Digit Symbol Substitution Test) score. Results showed that candesartan/hydrochlorothiazide, rosuvastatin, and their combination did not reduce or increase the rate of cognitive or functional decline over median follow-up of 5.7 years; the authors suggested that the failure to observe any benefit could be attributed to the relatively short follow-up, the difficulty in retrieving all data and making a correct diagnosis by telephone interviews, and the healthy volunteer bias. A recently published randomized controlled trial on hypertensive patients aged ≥ 60 years found that rosuvastatin alleviated the progression of cognitive impairment and reduced the risk of dementia over an average of 7-year follow-up.⁹⁵ The ongoing STAREE trial, involving healthy individuals aged ≥ 70 years treated with 40 mg atorvastatin or placebo, with development of dementia among primary outcome measures, has an estimated completion date of 2023.

Our study has several limitations. First, the heterogeneity of diagnostic criteria for dementia, and the use of clinical diagnosis not necessarily supported by standardized cognitive test (for example based on ICD codes), as well as different methods to assess the use of statins across included studies may limit the generalizability of the results. This criticism was addressed by Li et al.,⁹⁶ who evaluated the associations between statin use and the typical AD-related neuropathological outcomes, neurofibrillary tangles, and neuritic plaques using brain autopsy. After controlling for age at death, gender, cognitive score at entry, brain weight, and the presence of microvascular lesions, statin users had a significantly reduced risk for all the outcomes. More in general, this study is a pooled synthesis of observational studies which are susceptible to the effects of bias and confounding by known and unknown factors that are not adequately controlled for, and thus results should be interpreted cautiously, though observational studies can provide data on long-term effects and rarer adverse effects. As an example, the protective effect could be partially explained by the so-called 'healthy user bias', which is the propensity for patients who receive one preventive therapy (as statins) to also seek other preventive services or adopt healthy behaviours.⁹⁷ The effect of an unmeasured confounder, which might overinflate the observed protective effect was addressed by Corrao et al.⁹⁸ In their analysis, a confounder that is three times less frequent among statin users would increase the risk of dementia of five times, or even more, in order to fully explain the observed exposure–outcome association.

Conclusions

The results of this complete and up to date meta-analysis of observational studies:

- suggest that statins are unlikely to cause dementia or cognitive decline, supporting the good safety profile and indications of statin treatment in adult and elderly patients to prevent cardiovascular events;
- support the indication by the recent cardiovascular prevention guidelines¹ strongly recommending the use of statins in secondary prevention in all older subjects and in primary prevention in subjects up to 75 years at high/very high cardiovascular risk to prevent cardiovascular events⁹⁹;
- highlight that, regarding the possible role of statin therapy for the prevention of dementia, the weakness of pooled data from clinical trials²⁴ and the risk of bias inherent in the observational design, do not allow such a recommendation;
- suggest that indications that aggressive lipoprotein management and statin use as strategy for preventing cognitive decline in elderly persons, requires specifically designed randomized clinical trials, with larger populations, longer follow-up, and standardized and recognized methods for the diagnosis of dementia.

Supplementary material

Supplementary material is available at *European Journal of Preventive Cardiology* online.

Data availability statement

The data underlying this article are available in the article and in its online supplementary material.' has been added at the end of Method section.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article. The work of M.C. is supported by Ministry of Health-IRCCS MultiMedica (GR-2016-02361198). The work of A.Z. is supported by Fondazione SISA. The work of A.L.C. is supported by Fondazione Cariplo (2015-0524 and 2015-0564; H2020 REPROGRAM PHC-03-2015/667837-2; ERANET ER-2017-2364981; PRIN 2017H5F943); Ministry of Health-IRCCS MultiMedica (GR-2011-02346974); and SISA Lombardia and Fondazione SISA.

Conflict of interest: All authors declare no support from any organization for the submitted work; no other relationships or activities that could appear to have influenced the submitted work. E.O., G.M., O.C., F.G., M.G., N.D.B., and M.C. report no disclosures. A.L.C. received research funding and/or honoraria for advisory boards, consultancy or speaker bureau from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Mediolanum, Merck or MSD, Pfizer, Recordati, Rottapharm, Sanofi-Regeneron, and Sigma-Tau. A.Z. received honoraria/expenses from Amgen, Eli Lilly, Abbott-Mylan, Servier, Sanofi-Regeneron, Amryt, Amarin, and Daiichi Sankyo.

References

- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglul L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2020;**41**:111–188.
- Smith DG. Epidemiology of dyslipidemia and economic burden on the healthcare system. *Am J Manag Care* 2007;**13**:S68–S71.
- Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. *Nat Rev Cardiol* 2021;**18**:689–700.
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;**139**:e1082–e1143.
- Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015;**385**:1397–1405.
- Cholesterol Treatment Trialists' (CTT) Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;**380**:581–590.
- Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. *Circ Res* 2017;**120**:229–243.
- Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgozoglul L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence—focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J* 2018;**39**:2526–2539.
- Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglul L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015;**36**:1012–122B.
- Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. *Pharmacotherapy* 2006;**26**:1190–1192.
- Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. *Ann Pharmacother* 2006;**40**:1880–1883.
- King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. *Pharmacotherapy* 2003;**23**:1663–1667.
- Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. *Drug Saf* 2007;**30**:669–675.
- Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. *Mayo Clin Proc* 2013;**88**:1213–1221.
- Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med* 2015;**30**:348–358.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;**360**:7–22.
- Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *J Neurol* 2010;**257**:85–90.
- Muldoon MF, Ryan CA, Sereika SA, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med* 2004;**117**:823–829.
- Taylor BA, Dager AD, Panza GA, Zaleski AL, Meda S, Book G, Stevens MC, Tartar S, White CM, Polk DM, Pearson GD, Thompson PD. The effect of high-dose atorvastatin on neural activity and cognitive function. *Am Heart J* 2018;**197**:166–174.
- Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) Trial. *Pharmacotherapy* 2007;**27**:183–190.
- Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Statins, cognition, and dementia—systematic review and methodological commentary. *Nat Rev Neurol* 2015;**11**:220–229.

22. Chu C-S, Tseng P-T, Stubbs B, Chen T-Y, Tang C-H, Li D-J, Yang W-C, Chen Y-W, Wu C-K, Veronese N, Carvalho AF, Fernandes BS, Herrmann N, Lin P-Y. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. *Sci Rep* 2018;**8**:5804.
23. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. *Dement Geriatr Cogn* 2007;**23**:194–201.
24. McGuinness B, Craig D, Bullock R, Passmore P; Cochrane Dementia and Cognitive Improvement Group. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2016;**4**:CD003160.
25. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. *Dement Geriatr Cogn Disord* 2007;**23**:194–201.
26. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;**4**:1–1.
27. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;**283**:2008–2012.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;**34**:939–944.
29. World Health Organization. *The ICD-10 Classification of Mental and Behavioural Disorders: clinical Descriptions and Diagnostic Guidelines*. Geneva: World Health Organization; 1992. xii, 362 p.
30. American Psychiatric Association, DSM-5 Task Force. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. 5th ed. American Psychiatric Publishing, Inc.; 2013.
31. Arevalo-Rodriguez I, Smailagic N, Roqué I Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, Pedraza OL, Bonfill Cosp X, Cullum S; Cochrane Dementia and Cognitive Improvement Group. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev* 2015;**2015**:CD010783.
32. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm [cited 2009 Oct 19].
33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557–560.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629–634.
35. Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins? *Front Cardiovasc Med* 2021;**8**:687585.
36. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet* 2000;**356**:1627–1631.
37. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. *Arch Neurol* 2002;**59**:223–227.
38. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. *Arch Neurol* 2002;**59**:378–384.
39. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. *Neuroepidemiology* 2004;**23**:94–98.
40. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, van Belle G, McCormick W, Bowen JD, Teri L, Schellenberg GD, Larson EB. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. *Neurology* 2004;**63**:1624–1628.
41. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. *Arch Neurol* 2004;**61**:705–714.
42. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Statin use and the risk of incident dementia: the Cardiovascular Health Study. *Arch Neurol* 2005;**62**:1047–1051.
43. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JCS; Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. *Arch Gen Psychiatry* 2005;**62**:217–224.
44. Green RC, McNagy SE, Jayakumar P, Cupples LA, Benke K, Farrer LA; MIRAGE Study Group. Statin use and the risk of Alzheimer's disease: the MIRAGE study. *Alzheimers Dement* 2006;**2**:96–103.
45. Szawast SJ, Hendrie HC, Lane KA, Gao S, Taylor SE, Unverzagt F, Murrell J, Deeg M, Ogunniyi A, Farlow MR, Hall KS. Association of statin use with cognitive decline in elderly African Americans. *Neurology* 2007;**69**:1873–1880.
46. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. *BMC Med* 2007;**5**:20.
47. Zigman WB, Schupf N, Jenkins EC, Urv TK, Tycko B, Silverman W. Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome. *Neurosci Lett* 2007;**416**:279–284.
48. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. *Curr Alzheimer Res* 2008;**5**:416–421.
49. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. *Neurology* 2008;**70**:1795–1802.
50. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. *Neurology* 2008;**71**:344–350.
51. Smeeth DL, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. *Br J Clin Pharmacol* 2009;**67**:99–109.
52. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. *J Neurol Neurosurg Psychiatry* 2009;**80**:13–17.
53. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. *BMJ* 2010;**340**:c2197.
54. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JCS, Larson EB. Age-varying association between statin use and incident Alzheimer's disease. *J Am Geriatr Soc* 2010;**58**:1311–1317.
55. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, Zonderman AB. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *J Epidemiol Community Health* 2011;**65**:949–957.
56. Parikh NM, Morgan RO, Kunik ME, Chen H, Aparasu RR, Yadav RK, Schulz PE, Johnson ML. Risk factors for dementia in patients over 65 with diabetes. *Int J Geriatr Psychiatry* 2011;**26**:749–757.
57. Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, Carlson MC, Yasar S, Dekosky S, Burke GL. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. *J Stroke Cerebrovasc Dis* 2012;**21**:436–444.
58. Ancelin M-L, Carrière I, Barberger-Gateau P, Auriacombe S, Rouaud O, Furlanos S, Berr C, Dupuy A-M, Ritchie K. Lipid lowering agents, cognitive decline, and dementia: the three-city study. *J Alzheimers Dis* 2012;**30**:629–637.
59. Douiri A, McKeivitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. *Circulation* 2013;**128**:1341–1348.
60. Chen PY, Liu SK, Chen CL, Wu CS. Long-term statin use and dementia risk in Taiwan. *J Geriatr Psychiatry Neurol* 2014;**27**:165–171.
61. Chen JM, Chang CV, Chang TH, Hsu CC, Horng JT, Sheu WH. Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan. *PLoS One* 2014;**9**:e88434.
62. Chou CY, Chou YC, Chou YJ, Yang YF, Huang N. Statin use and incident dementia: a nationwide cohort study of Taiwan. *Int J Cardiol* 2014;**173**:305–310.
63. Ma F, Wu T, Miao R, Xiao YY, Zhang W, Huang G. Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up. *J Alzheimers Dis* 2015;**43**:1441–1449.
64. Lin F-C, Chuang Y-S, Hsieh H-M, Lee T-C, Chiu K-F, Liu C-K, Wu M-T. Early statin use and the progression of Alzheimer disease: a total population-based case-control study. *Medicine (Baltimore)* 2015;**94**:e2143.
65. Chao T-F, Liu C-J, Chen S-J, Wang K-L, Lin Y-J, Chang S-L, Lo L-W, Hu Y-F, Tuan T-C, Chen T-J, Lip GH, Chiang C-E, Chen S-A. Statins and the risk of dementia in patients with atrial fibrillation: a nationwide population-based cohort study. *Int J Cardiol* 2015;**196**:91–97.
66. Chuang CS, Lin CL, Lin MC, Sung FC, Kao CH. Decreased prevalence of dementia associated with statins: a national population-based study. *Eur J Neurol* 2015;**22**:912–918.
67. Yang Y-H, Teng H-W, Lai Y-T, Li S-Y, Lin C-C, Yang AC, Chan H-L, Hsieh Y-H, Lin C-F, Hsu F-Y, Liu C-K, Liu W-S. Statins reduces the risk of dementia in patients with late-onset depression: a retrospective cohort study. *PLoS One* 2015;**10**:e0137914.
68. Hendrie HC, Hake A, Lane K, Purnell C, Unverzagt F, Smith-Gamble V, Murrell J, Ogunniyi A, Baiyewu O, Callahan C, Saykin A, Taylor S, Hall K, Gao S. Statin use, incident dementia and Alzheimer disease in elderly African Americans. *Ethn Dis* 2015;**25**:345–354.

69. Chitnis AS, Aparasu RR, Chen H, Kunik ME, Schulz PE, Johnson ML. Use of statins and risk of dementia in heart failure: a retrospective cohort study. *Drugs Aging* 2015;**32**:743–754.
70. Wu C-K, Yang Y-H, Lin T-T, Tsai C-T, Hwang J-J, Lin J-L, Chen P-C, Chiang F-T, Lin L-Y. Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. *J Intern Med* 2015;**277**:343–352.
71. Booker A, Jacob LE, Rapp M, Bohlken J, Kostev K. Risk factors for dementia diagnosis in German primary care practices. *Int Psychogeriatr* 2016;**28**:1059–1065.
72. Pan ML, Hsu CC, Chen YM, Yu HK, Hu GC. Statin use and the risk of dementia in patients with stroke: a nationwide population-based cohort study. *J Stroke Cerebrovasc Dis* 2018;**27**:3001–3007.
73. Wandell P, Carlsson AC, Sundquist J, Sundquist K. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation. *Int J Cardiol* 2018;**272**:149–154.
74. Liu JM, Chen TH, Chuang HC, Wu CT, Hsu RJ. Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. *Prostate Cancer Prostatic Dis* 2019;**22**:276–283.
75. Redelmeier DA, Manzoor F, Thiruchelvam D. Association between statin use and risk of dementia after a concussion. *JAMA Neurol* 2019;**76**:887.
76. Chang C-F, Liou Y-S, Lin T-K, Ma S, Hu Y-R, Chen H-Y, Jong G-P. High exposure to statins decrease the risk of new-onset dementia: a nationwide population-based longitudinal cohort study. *Medicine (Baltimore)* 2019;**98**:e16931.
77. Kim M-Y, Jung M, Noh Y, Shin S, Hong CH, Lee S, Jung Y-S. Impact of statin use on dementia incidence in elderly men and women with ischemic heart disease. *Biomedicines* 2020;**8**:30.
78. Lee C-Y, Chang C-C, Lin C-S, Yeh C-C, Hu C-J, Wu C-Z, Chen T-L, Liao C-C. Risk of dementia in patients with periodontitis and related protective factors: a nationwide retrospective cohort study. *J Clin Periodontol* 2020;**47**:1428–1436.
79. Lee J-W, Choi E-A, Kim Y-S, Kim Y, You H-S, Han Y-E, Kim H-S, Bae Y-J, Kim J, Kang H-T. Statin exposure and the risk of dementia in individuals with hypercholesterolaemia. *J Intern Med* 2020;**288**:689–698.
80. Torrandell-Haro G, Branigan GL, Vitali F, Geiffman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. *Alzheimers Dement* 2020;**6**:e12108.
81. Zingel R, Bohlken J, Riedel-Heller S, Barth S, Kostev K. Association between low-density lipoprotein cholesterol levels, statin use, and dementia in patients followed in German General Practices. *J Alzheimers Dis* 2021;**79**:37–46.
82. Adhikari A, Tripathy S, Chuzi S, Peterson J, Stone NJ. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. *J Clin Lipidol* 2021;**15**:22–32.e12.
83. Zhang XY, Wen JZ, Zhang ZQ. Statins use and risk of dementia: a dose-response meta analysis. *Medicine* 2018;**97**:e11304.
84. Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, Zhao QF, Li JQ, Wang J, Yu JT. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2015;**86**:1299–1306.
85. Carlsson CM, Nondahl DM, Klein BEK, McBride PE, Sager MA, Schubert CR, Klein R, Cruickshanks KJ. Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. *Alzheimer Dis Assoc Disord* 2009;**23**:11–17.
86. Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, Segatto M. Statins and the brain: more than lipid lowering agents? *Curr Neuropharmacol* 2019;**17**:59–83.
87. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. *Nat Rev Drug Discov* 2005;**4**:977–987.
88. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR. Cognitive function in a randomized trial of evolocumab. *N Engl J Med* 2017;**377**:633–643.
89. Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD. Lipid lowering and Alzheimer disease risk: a Mendelian randomization study. *Ann Neurol* 2020;**87**:30–39.
90. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjaerg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. *BMJ* 2017;**357**:j1648.
91. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L; Cardiovascular Health Study Collaborative Research Group. Statins and cognitive function in the elderly: the Cardiovascular Health Study. *Neurology* 2005;**65**:1388–1394.
92. Kuller LH. Statins, lipids and dementia? *J Clin Lipidol* 2021;**15**:18–21.
93. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ; PROSPER study group. PROSpective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;**360**:1623–1630.
94. Bosch J, O'Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avezum A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Sliwa K, Lee SF, Pogue JM, Hart R, Yusuf S; HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study. *Neurology* 2019;**92**:e1435–e1446.
95. Hu W, Li Y, Zhao Y, Dong Y, Cui Y, Sun S, Gong G, Zhang H, Chai Q, Wang J, Liu Z. Telmisartan and rosuvastatin synergistically ameliorate dementia and cognitive impairment in older hypertensive patients with apolipoprotein E genotype. *Front Aging Neurosci* 2020;**12**:154.
96. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JCS, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. *Neurology* 2007;**69**:878–885.
97. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. *J Gen Intern Med* 2011;**26**:546–550.
98. Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Pasini TS, Catapano AL, Mancia G. Long-term use of statins reduces the risk of hospitalization for dementia. *Atherosclerosis* 2013;**230**:171–176.
99. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;**393**:407–415.
100. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med* 2009;**6**:e1000097.